Categories
rss rss-es rss-pt

INS RIFARÁ 6000 RODILLERAS ARTICULADAS ENTRE MOTOCICLISTAS DE TODO EL PAÍS

Murilo Freitas - 20:02, 15 de enero de 2020612

INS RIFARÁ 6000 RODILLERAS ARTICULADAS ENTRE MOTOCICLISTAS DE TODO EL PAÍS

INS RIFARÁ 6000 RODILLERAS ARTICULADAS ENTRE MOTOCICLISTAS DE TODO EL PAÍSEn Costa Rica ocurren cerca de 37.500 accidentes de tránsito al año, es decir 100 accidentes diarios…

https://www.ministeriodesalud.go.cr/index.php/centro-de-prensa/noticias/741-noticias-2020/1530-ins-rifara-6000-rodilleras-articuladas-entre-motociclistas-de-todo-el-pais

 
Categories
rss rss-es rss-pt

Surgical Gowns and Packs by Cardinal Health: FDA Statement – Potential Quality Issues Affecting Some of its Level 3 Surgical Gowns and Accompanying PreSource Procedural Packs

Murilo Freitas - 19:00, 15 de enero de 2020467
The medical device manufacturer Cardinal Health alerted its customers to potential quality issues affecting some of its Level 3 surgical gowns and accompanying PreSource procedural packs.

http://www.fda.gov/safety/medical-product-safety-information/surgical-gowns-and-packs-cardinal-health-fda-statement-potential-quality-issues-affecting-some-its

 
Categories
rss rss-es rss-pt

FUSION IV Pharmaceuticals, Inc dba. AXIA Pharmaceutical Issues Voluntary Nationwide Recall of All Sterile Drug Products Within Expiry Due to A Lack of Assurance of Sterility

Murilo Freitas - 05:00, 15 de enero de 2020722
FUSION IV Pharmaceuticals, Inc dba. AXIA Pharmaceutical is voluntarily recalling all unused sterile drug products within expiry, to the user level, due to a lack of assurance of sterility. The recalled sterile products have been found to be inconsistent with federal guidelines.

http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/fusion-iv-pharmaceuticals-inc-dba-axia-pharmaceutical-issues-voluntary-nationwide-recall-all-sterile

 
Categories
rss rss-es rss-pt

Belviq, Belviq XR (lorcaserin): Drug Safety Communication – Due to Possible Increased Risk of Cancer

Murilo Freitas - 15:00, 13 de enero de 2020600
FDA is alerting the public that results from a clinical trial assessing safety show a possible increased risk of cancer with the weight management medicine Belviq, Belviq XR (lorcaserin).

http://www.fda.gov/safety/medical-product-safety-information/belviq-belviq-xr-lorcaserin-drug-safety-communication-due-possible-increased-risk-cancer

 
PRAIS 2.0